S3 First Mover Advantage

I’m keen to hear people’s thoughts on Cann Group’s recent schedule 3 trial results and how this might affect BOD.

As far as I’m aware, Cann was likely to be first in the race to the s3 market, with BOD a few months behind them, but I suspect these poor trial results will set them back substantially. Assuming our results come out positive, could this potentially give us a first mover advantage in the market in light of our commercial agreement with Arrotex?

I am somewhat concerned that we’re testing for similar indications to them but from what I can tell a lot of companies (e.g. LGP) are also testing for sleep conditions so I can only assume this is the most promising area for registration. Can someone shed some light?